Universe Pharmaceuticals Inc. (UPC) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Universe Pharmaceuticals Inc. (UPC) Healthcare & Pipeline Overview

Universe Pharmaceuticals Inc. is a China-based pharmaceutical company specializing in traditional Chinese medicine derivative products and third-party pharmaceuticals. Targeting common chronic conditions and physical wellness, UPC distributes to pharmaceutical companies, hospitals, clinics, and drugstore chains, operating within the competitive Chinese healthcare market.

What Is the Investment Thesis for UPC?

Universe Pharmaceuticals Inc. presents a speculative investment opportunity within the Chinese pharmaceutical market, specifically in the traditional Chinese medicine sector. The company's focus on TCM derivative products and distribution of third-party pharmaceuticals caters to a growing demand for traditional remedies and healthcare products in China. However, the company's negative profit margin of -20.6% raises concerns about its financial sustainability. The company's high beta of 1.57 suggests higher volatility compared to the broader market. Future growth hinges on successful expansion of its product lines, effective cost management, and navigating the competitive landscape. The company's P/E ratio is -0.41, indicating that it is not currently profitable.

Based on FMP financials and quantitative analysis

UPC Key Highlights

Universe Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.

• The company's gross margin stands at 35.3%, indicating the profitability of its products before operating expenses.
• UPC has a negative profit margin of -20.6%, reflecting challenges in achieving overall profitability.
• The company's beta is 1.57, suggesting a higher volatility compared to the market average.
• Universe Pharmaceuticals Inc. does not currently offer a dividend yield.

Who Are UPC's Competitors?

UPC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are UPC's Key Strengths?

Focus on traditional Chinese medicine (TCM) derivative products.

• Established distribution network within China.
• Relationships with pharmaceutical companies, hospitals, clinics, and drugstore chains.
• Subsidiary of Sununion Holding Group Limited.

What Are UPC's Weaknesses?

Negative profit margin (-20.6%).

• Relatively young company (incorporated in 2019).
• Limited brand recognition compared to larger pharmaceutical companies.
• Dependence on the Chinese market.

What Could Drive UPC Stock Higher?

Potential new product launches in the TCM derivative product line.

• Expansion of the distribution network to new regions within China.
• Increased focus on e-commerce sales channels.

What Are the Key Risks for UPC?

Financial-distress signal — its Altman Z-Score of 1.02 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-3.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Increasing regulatory scrutiny in the Chinese pharmaceutical market.
• Competition from larger pharmaceutical companies.
• Fluctuations in raw material prices.
• Negative profit margin impacting financial stability.

What Are the Growth Opportunities for UPC?

• Expansion of Product Portfolio: Universe Pharmaceuticals can expand its product portfolio by developing new TCM derivative products targeting specific health conditions or age groups. Successful product development and marketing could drive revenue growth within the next 2-3 years.
• Geographic Expansion within China: Universe Pharmaceuticals can expand its distribution network to new regions within China, targeting underserved markets with high demand for TCM products. China's vast geography and diverse population offer ample opportunities for expansion. This expansion could be achieved through partnerships with local distributors or establishing new sales offices within the next 1-2 years.
• Increased Focus on E-commerce: Universe Pharmaceuticals can leverage e-commerce platforms to reach a wider customer base and increase sales. The online retail market in China is booming, offering a cost-effective channel for reaching consumers. Investing in online marketing and sales infrastructure could drive revenue growth within the next year.
• Strategic Partnerships and Acquisitions: Universe Pharmaceuticals can pursue strategic partnerships or acquisitions to expand its product offerings, distribution network, or market share. Collaborating with other pharmaceutical companies or acquiring complementary businesses could accelerate growth and enhance competitiveness within the next 2-3 years.
• Development of Innovative TCM Therapies: Universe Pharmaceuticals can invest in research and development to develop innovative TCM therapies that address unmet medical needs. The demand for innovative and effective treatments is growing, offering a potential competitive advantage. Successful development and commercialization of new therapies could drive long-term revenue growth within the next 3-5 years.

What Are UPC's Competitive Advantages?

• Established distribution network within China.
• Focus on traditional Chinese medicine (TCM) derivative products.
• Relationships with pharmaceutical companies, hospitals, clinics, and drugstore chains.

What Does UPC Do?

Universe Pharmaceuticals Inc., established in 2019 and based in Ji'An, China, focuses on the production, marketing, distribution, and sale of traditional Chinese medicine (TCM) derivative products. As a subsidiary of Sununion Holding Group Limited, the company addresses common chronic health conditions, particularly among the elderly, with products aimed at physical wellness and longevity. UPC also offers cold and flu medications, catering to a broad consumer base seeking traditional remedies. Beyond its own manufactured products, Universe Pharmaceuticals distributes a range of third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements, diversifying its offerings and revenue streams. The company's distribution network includes pharmaceutical companies, hospitals, clinics, and drugstore chains, reflecting a comprehensive approach to reaching the Chinese healthcare market. Despite its relatively young age, Universe Pharmaceuticals aims to establish itself as a key player in the TCM market by leveraging its product range and distribution network.

What Products and Services Does UPC Offer?

• Manufactures traditional Chinese medicine (TCM) derivative products.
• Markets and distributes TCM products throughout China.
• Sells products targeting common chronic health conditions in the elderly.
• Offers cold and flu medications.
• Distributes third-party biomedical drugs.
• Distributes third-party medical instruments.
• Distributes third-party traditional Chinese medicine pieces products.
• Distributes third-party dietary supplements.

How Does UPC Make Money?

• Manufactures and sells its own line of traditional Chinese medicine (TCM) derivative products.
• Distributes third-party pharmaceutical and healthcare products.
• Generates revenue through sales to pharmaceutical companies, hospitals, clinics, and drugstore chains.

What Industry Does UPC Operate In?

Universe Pharmaceuticals Inc. operates within the competitive Chinese pharmaceutical market, which is experiencing growth driven by an aging population and increasing demand for healthcare services and traditional medicines. The market includes both domestic and international players, with a mix of established pharmaceutical giants and smaller, specialized companies. Trends include increasing regulatory scrutiny, a focus on quality and safety, and growing demand for innovative therapies. Universe Pharmaceuticals competes with other TCM manufacturers and distributors, requiring a focus on product differentiation and efficient distribution channels to gain market share.

Who Are UPC's Key Customers?

• Pharmaceutical companies
• Hospitals
• Clinics
• Drugstore chains

Over the past six months, Universe Pharmaceuticals Inc. insiders filed 2 SEC Form 4 transactions — 0 sales and 2 purchases. On net that is roughly 85K shares acquired (about $0) — insiders putting money in tends to read as conviction.

Universe Pharmaceuticals Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.02 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Universe Pharmaceuticals Inc. stands at -3.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.7%, showing how much profit it generates from its asset base. A current ratio of 4.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -66.7%, the inverse of the P/E and a quick read on earnings relative to price.

Universe Pharmaceuticals Inc. (UPC) Valuation Context

Valued at $3.37M, UPC is classified as a micro-cap stock. Relative to its peer group, UPC's quantitative score of 40/100 is below the peer average of 60/100.

Company Profile

Universe Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Ji'An, CN. The company is led by CEO Gang Lai. UPC has traded publicly since 2021.

UPC Financials

UPC Latest News

UPC Analyst Consensus

UPC MoonshotScore

Common Questions About UPC (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources